<DOC>
	<DOCNO>NCT02284529</DOCNO>
	<brief_summary>Open- Label , Single Arm Study . To evaluate safety profile Orectalip® ( oxaliplatin ) , fluorouracil leucovorin adjuvant therapy treatment high-risk stage-Ⅱ colorectal cancer . Primary end point : To evaluate incidence grade 0-3 neurosensory symptom ( paresthesia ) end study . Other end point : The incidence Grade 3 4 neutropenia , thrombocytopenia , anemia , nausea , diarrhea vomit 12 week . Safety evaluate include vital sign record visit .</brief_summary>
	<brief_title>Safety Orectalip® ( Oxaliplatin ) Adjuvant Treatment High-risk Stage-Ⅱ Colorectal Cancer</brief_title>
	<detailed_description>There 18 20 patient complete trial eligible statistical analysis , 2 patient withdraw wound infection . There 11 ( 61 % ) male patient 7 ( 39 % ) female patient . The patient age 30 73 year mean age 50.4 year . The grade adverse event evaluation mainly allocate Grade 0 Grade 1 . The incidence Grade 3 4 find follow symptom : leucopenia , neutropenia , anemia . One ( 6 % ) adverse event leucopenia occur visit 1 visit 2 , respectively . One ( 6 % ) adverse event neutropenia occur visit 1 , visit 2 , visit 3 , respectively ; 2 ( 13 % ) event occur visit 5 . One patient suffer adverse event anemia visit 5 visit 6 .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Inclusion Criteria 1 . Subject must World Health Organization performance status score less 1 . 2 . Subject must WBC 4,000 cell , platelet count 100,000 , absolute neutrophil count 1,500 serum bilirubin level less than1.5mg , serum creatinine level less than1.5mg Exclusion Criteria 1 . Subject receive oxaliplatin treatment 2 . Subject history allergy platinum derivates agent 3 . Subject decompensated liver function ( ALT、 AST alkaline phosphatase 2.5 time upper limit normal range ) . 4 . Subject serious concomitant illness precede entry study . 5 . Female subject pregnant breast feeding . 6 . Female subject go pregnant within 6 month treatment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>high-risk stage-Ⅱ Colorectal Cancer , Orectalip , oxaliplatin</keyword>
</DOC>